Veterinary Orthopaedic Society - 40th Annual Conference Abstracts

Introduction: Osteoarthritis (OA) can cause lifelong lameness regardless of treatment. Autologous adipose-derived stem cell (ASC) therapy shows promise in treating OA. Clinical use of allogeneic ASC therapy has not been investigated. The purpose of this study was to objectively assess safety and therapeutic effects of autologous and allogeneic canine ASCs on treatment of OA. We hypothesized that ASC therapy is safe and results in measurable clinical improvement. Materials and Methods: This prospective, randomized controlled trial utilized dogs diagnosed with fragmented coronoid process (FCP) and OA. All dogs had arthroscopic fragment removal and were randomized into four groups (n=10/group): 1) control group with no further treatment, 2) Proximal ulnar osteotomy (PUO), 3) PUO + autologous ASCs and 4) PUO+ allogeneic ASCs. Each dog had force platform gait analysis, Canine Brief Pain Inventory questionnaires, and delayed gadolinium enhanced magnetic resonance imaging (DGEMRIC) scores prior to therapeutic intervention, and six months after intervention. Results: 34/40 of participants have completed the study. Successful outcomes were found in 30% of cases in the control group, 20% of the PUO group, 60% of autologous ASCs, and 75% of allogeneic ASCs, with no deleterious side effects. Discussion/Conclusion: Preliminary data indicates ASC therapy is safe as an autologous or allogeneic intra-articular injection with improved outcome in OA caused by fragmented coronoid process. Acknowledgments: Hohn-Johnson Research Award